Characterization and Longitudinal Monitoring of Muscular Phenotype in Patients Admitted to
Approximately 40% of patients develop muscle dysfunction during their stay in intensive care, particularly in the context of sepsis. This dysfunction represents an acquired muscle injury that is secondary to the primary illness that led to ICU admission. It affects both the limb muscles and the respiratory muscles of t
| Condition(s) | Sepsis, Myopathy Critical Illness |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Approximately 40% of patients develop muscle dysfunction during their stay in intensive care, particularly in the context of sepsis. This dysfunction represents an acquired muscle injury that is secondary to the primary illness that led to ICU admission. It affects both the limb muscles and the respiratory muscles of the thoracic cage. Clinically, this manifests as bilateral and symmetrical muscle weakness in the limbs, and contributes significantly to difficulties in weaning patients off mechanical ventilation. The loss of muscle mass is directly correlated with the severity of the patient's clinical condition and can reach up to 20% of initial muscle mass within just ten days. This rapid and profound atrophy primarily results from an imbalance between increased muscle protein breakdown ( |
| Who can participate | Inclusion Criteria: * Participants admitted to ICU with an expected length of stay greater than 7 days. * Expected duration of invasive mechanical ventilation greater than 48 hours. * Diagnosis of sepsis upon ICU admission (presence of an infection and a SOFA score ≥ 2, or an increase of ≥ 2 points if organ dysfunction was present prior to infection). * Informed consent obtained from the participant or from a designated surrogate decision-maker Exclusion Criteria: * Pregnant women. * Participants not affiliated with the national health insurance system. * Participants under legal protection (guardianship or conservatorship). * Moribund participants (end-of-life patients). * Participants with active cancer. * Participants with chronic neuromuscular disorders or admitted to the ICU for an ac |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Centre Hospitalier de Saint-Brieuc |
| Locations | Saint-Brieuc, France |
| Start date | 2025-03-25 |
| NCT ID | NCT07074028 |
| Official listing | https://clinicaltrials.gov/study/NCT07074028 |